公开(公告)号：US20230381151A1

公开(公告)日：2023-11-30

申请号：US18087774

申请日：2022-12-22

Applicant: Forma Therapeutics, Inc.

Inventor： Anna ERICSSON ,  Neal GREEN ,  Gary GUSTAFSON ,  Bingsong HAN ,  David R. Lancia, JR. ,  Lorna MITCHELL ,  David RICHARD ,  Tatiana SHELEKHIN ,  Chase C. SMITH ,  Zhongguo WANG ,  Xiaozhang ZHENG

IPC: A61K31/436 ,  A61P7/06 ,  A61K9/00 ,  C07D487/04 ,  C07D491/056

CPC classification number: A61K31/436 ,  A61P7/06 ,  A61K9/0053 ,  C07D487/04 ,  C07D491/056

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

公开(公告)号：US20240016795A1

公开(公告)日：2024-01-18

申请号：US18371621

申请日：2023-09-22

Applicant: FORMA Therapeutics, Inc.

Inventor： Sylvie GUICHARD ,  Maureen CALIGIURI ,  Anna ERICSSON ,  Qunli XU ,  Hesham MOHAMED

IPC: A61K31/4745 ,  A61P35/00

CPC classification number: A61K31/4745 ,  A61P35/00

Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230065368A1

公开(公告)日：2023-03-02

申请号：US17277500

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Bruce FOLLOWS ,  Katherine J. KAYSER-BRICKER ,  Adam Charles TALBOT ,  Scot MENTE ,  Tatiana SHELEKHIN ,  Anna ERICSSON

IPC: C07D519/00 ,  A61P35/00 ,  C07D487/04

Abstract: The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X). USP9X inhibiting compounds are useful in the treatment of disease and disorders associated with modulation of USP9X, such as cancer.

公开(公告)号：US20220088005A1

公开(公告)日：2022-03-24

申请号：US17482720

申请日：2021-09-23

Applicant: FORMA Therapeutics, Inc.

Inventor： Sylvie GUICHARD ,  Maureen CALIGIURI ,  Anna ERICSSON ,  Qunli XU ,  Hesham MOHAMED

IPC: A61K31/4745 ,  A61P35/00

Abstract: Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170174658A1

公开(公告)日：2017-06-22

申请号：US15452256

申请日：2017-03-07

Applicant: Forma Therapeutics, Inc.

Inventor： Jian LIN ,  Anna ERICSSON ,  Ann-Marie CAMPBELL ,  Gary R. GUSTAFSON ,  Zhongguo WANG ,  R. Bruce DIEBOLD ,  Susan ASHWELL ,  David LANCIA, JR. ,  Justin Andrew CARAVELLA ,  Wei LU

IPC: C07D401/12 ,  C07D471/04 ,  C07D401/14

CPC classification number: C07D401/12 ,  A61K31/47 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20240083901A1

公开(公告)日：2024-03-14

申请号：US18124071

申请日：2023-03-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna ERICSSON ,  Neal GREEN ,  Gary GUSTAFSON ,  Bingsong HAN ,  David R. LANCIA, JR. ,  Lorna MITCHELL ,  David RICHARD ,  Tatiana SHELEKHIN ,  Chase C. SMITH ,  Zhongguo WANG ,  Xiaozhang ZHENG

IPC: C07D487/04 ,  A61K9/00 ,  A61K31/407 ,  A61P7/00 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K9/0053 ,  A61K31/407 ,  A61P7/00 ,  C07D519/00

Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

公开(公告)号：US20230055923A1

公开(公告)日：2023-02-23

申请号：US17277425

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang ZHENG ,  Anna ERICSSON ,  Neal GREEN ,  Gary GUSTAFSON ,  David R. LANCIA, Jr. ,  Jian LIN ,  Lorna MITCHELL ,  David RICHARD ,  Tatiana SHELEKHIN

IPC: C07D487/04

Abstract: The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

公开(公告)号：US20220213089A1

公开(公告)日：2022-07-07

申请号：US17439646

申请日：2020-03-13

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E.R. SCHILLER ,  Torsten HERBERTZ ,  Hongbin LI ,  Bradford GRAVES ,  Steven MISCHKE ,  Angela V. WEST ,  Anna ERICSSON ,  Jennifer R. DOWNING

IPC: C07D471/04

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

公开(公告)号：US20220031671A1

公开(公告)日：2022-02-03

申请号：US17275741

申请日：2019-09-19

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna ERICSSON ,  Neal GREEN ,  Gary GUSTAFSON ,  David R. LANCIA, Jr. ,  Gary MARSHALL ,  Lorna MITCHELL ,  David RICHARD ,  Zhongguo WANG ,  Sanjeev FORSYTH ,  Patrick F. KELLY ,  Madhu MONDAL ,  Maria RIBADENEIRA ,  Patricia SCHROEDER

IPC: A61K31/436 ,  A61K9/00 ,  A61P7/06 ,  C07D491/056

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

公开(公告)号：US20210346356A1

公开(公告)日：2021-11-11

申请号：US17277503

申请日：2019-09-19

Applicant: FORMA THERAPEUTICS, INC.

Inventor： Maureen LYNES ,  Weiping WANG ,  Bruce FOLLOWS ,  Katherine J. KAYSER-BRICKER ,  Adam Charles TALBOT ,  Scot MENTE ,  Tatiana SHELEKHIN ,  Anna ERICSSON

IPC: A61K31/436 ,  A61K31/538 ,  A61K31/407 ,  A61K31/497 ,  A61K45/06 ,  A61P35/00

Abstract: This disclosure provides methods of treating cancer with an inhibitor of ubiquitin specific peptidase 9X alone or in combination with an immune checkpoint pathway inhibitor.